Statins and blood pressure regulation

被引：44
作者：
Borghi C. [1 ]
Veronesi M. [1 ]
Prandin M.G. [1 ]
Dormi A. [1 ]
Ambrosioni E. [1 ]
机构：
[1] Divisione di Medicina Interna, Policlinico S. Orsola, 40138 Bologna
来源：
Current Hypertension Reports | 2001年 / 3卷 / 4期
关键词：
Simvastatin; Pravastatin; Lovastatin; Blood Pressure Control; Blood Pressure Regulation;
D O I：
10.1007/s11906-001-0090-y
中图分类号：
学科分类号：
摘要：
Hypertension and high serum cholesterol levels are two of the most relevant risk factors for cardiovascular diseases. A combined increase in both risk factors has been reported in a significant proportion of patients with coronary artery disease. Statins are the most widely used drugs to treat hypercholesterolemia, and they interact with blood pressure control in different populations of hypertensive patients. A significant reduction in blood pressure associated with the use of statins has been described in patients with untreated hypertension and in patients treated with antihypertensive drugs, particularly angiotensin converting enzyme inhibitors and calcium channel blockers. The effect of statins on blood pressure control has also been reported in diabetic patients. The mechanisms responsible for the hypotensive effect seem to be largely independent of the effect of statins on lipid profile, and are probably related to their interaction with endothelial function or angiotensin II receptors. The capacity of statins to improve blood pressure control could be a useful consideration for an integrated approach to better prevention of cardiovascular diseases. Copyright © 2001 by Current Science Inc.
引用
收藏
页码：281 / 288
页数：7
相关论文
共 45 条
  • [1] Heart and Stroke Statistical Update, (2000)
  • [2] Kannel W.B., Blood pressure as a cardiovascular risk factor: Prevention and treatment, JAMA, 275, pp. 1571-1576, (1996)
  • [3] Neaton J.D., Blackburn H., Jacobs D., Et al., Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Multiple risk factor intervention trial research group, Arch Intern Med, 152, pp. 1490-1500, (1992)
  • [4] Alderman M.H., Cohen H., Madhavan S., Diabetes and cardiovascular events in hypertensive patients, Hypertension, 33, pp. 1130-1134, (1999)
  • [5] Wilson P.W.F., D'Agostino R.B., Levy D., Et al., Prediction of coronary heart disease using risk factor categories, Circulation, 97, pp. 1837-1847, (1998)
  • [6] The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, Arch Intern Med, 157, pp. 2413-2446, (1997)
  • [7] Chalmers J., MacMahon S., Mancia G., Et al., 1999 world health organization-international society of hypertension guidelines for the management of hypertension. Guidelines sub-committee of the world health organization, Clin Exp Hypertens, 21, pp. 1009-1060, (1999)
  • [8] Summary of the second report of the national cholesterol education program (NCEP) expert panel in detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel II), JAMA, 269, pp. 3015-3033, (1993)
  • [9] Julius S., Jamerson K., Mejia A., Et al., The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh blood pressure study, JAMA, 264, pp. 354-358, (1990)
  • [10] Borghi C., Bacchelli S., Degli Esposti D., Et al., Pressor and metabolic correlates to long-term development of stable hypertension in borderline hypertensive patients, J Hypertens, 15, (1997)
12345